动脉粥样硬化的抗炎靶点 ApoB-100的研究进展
Advances of anti-inflammation therapy targeting ApoB-100 against atherosclerosis

动脉粥样硬化是由多种因素共同作用导致的血管壁的免疫炎症性疾病，是众多心血管疾病发生的主要病理基础。目前比较公认的动脉粥样硬化发生机制是“炎症反应”学说，即低密度脂蛋白（ low density lipoprotein，LDL）中所包含的载脂蛋白 ApoB-100的异常增高引起的病理性炎症反应是导致动脉粥样硬化的主要因素。通过免疫疗法抑制 ApoB-100导致的病理性炎症反应，有望延缓动脉粥样硬化的发生与发展。该文主要围绕 ApoB-100疫苗以及其他 ApoB-100抑制剂的最新进展和存在的问题进行综述。
：Atherosclerosis is an inflammatory disease of arterial wall causedmany factors, which is the main pathological basis of many cardiovascular diseases. Currently, "inflammatory response" theory is widely accepted as pathogenesis of atherosclerosis. Abnormal increase of apolipoprotein ApoB-100, a composition of low density lipoprotein (LDL), which causes pathological inflammation, is a major factor leading to atherosclerosis. Therefore, inhibition of ApoB-100 induced pathological inflammatory responseimmunotherapy is expected to delay the development of atherosclerosis. This review focused on the recent advances of ApoB-100 vaccine and other ApoB-100 inhibitors against atherosclerosis